A Study of the Effect of Neoadjuvant Bicalutamide (Casodex) on Tumour Hypoxia in Patients With Clinically Localized Prostate Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Bicalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 23 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 21 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017.